Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-02-23

Study Completion Date

2020-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to describe the evolution of hypodopaminergic syndrome in patients with Parkinson's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study

NCT01020682

Apathy in Parkinson Disease

UNKNOWN

Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease

NCT03517059

Parkinson Disease

COMPLETED

Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking

NCT01794195

Parkinson's Disease Apathy

COMPLETED NA

Effect of Deep Brain Stimulation on Neuropsychiatric Fluctuations in Patients With Parkinson's Disease

NCT04608123

Parkinson's Disease (Disorder)

COMPLETED

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

NCT00134966

Parkinson's Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients to be included have been clinically described in the early phase of their disease, before instauration of dopaminergic treatment, in the context of a former study ("Non Motor Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667") between june 2012 and june 2016.

3 to 5 years after this study, those patients who started dopaminergic treatment will be evaluated again.

The objective of this study, which takes place 3 to 5 year after the initial evaluation, is to measure the evolution of apathy and other symptoms of the hypodopaminergic syndrome.

Secondary objectives are the evolution of other parameters including pain, personality and behavior. All parameters measured have been determined of each patient in the Honeymoon study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Apathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apathetic patients

De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.

All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the "Starkstein scale of apathy"

Starkstein scale of Apathy

Intervention Type OTHER

The degree of apathy will be evaluated with the "Starkstein scale of Apathy"

Non-apathetic patients

De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.

All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the "Starkstein scale of apathy"

Starkstein scale of Apathy

Intervention Type OTHER

The degree of apathy will be evaluated with the "Starkstein scale of Apathy"

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Starkstein scale of Apathy

The degree of apathy will be evaluated with the "Starkstein scale of Apathy"

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who participated in "Non Motors Aspects in De Novo Parkinson's Disease (Honeymoon)" NCT02786667
* Patients under dopaminergic treatment, with stable dopaminergic treatment for at least 2 months
* Patients with medical insurance
* signed informed consent